JFC [JPMORGAN CHINA REGION FUND,] NSAR-B: (Original Filing)
[EX-99.77B ACCT LTTR 2 jfchinaauditletter.htm]
JFC [JPMORGAN CHINA REGION FUND,] NSAR-B: EX-99.77B ACCT LTTR 2 jfchinaauditletter.htm
[EX-99.77B ACCT LTTR 2 jfchinaauditletter.htm]
JFC [JPMORGAN CHINA REGION FUND,] NSAR-B: (Original Filing)
[jfchinaauditletter.htm 2 EX-99.77B ACCT LTTR]
JFC [JPMORGAN CHINA REGION FUND,] NSAR-B: jfchinaauditletter.htm 2 EX-99.77B ACCT LTTR
[jfchinaauditletter.htm 2 EX-99.77B ACCT LTTR]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
CNR [CHINA METRO-RURAL] 6-K: (Original Filing)
[MAN SANG INTERNATIONAL (B.V.I.) LIMITED UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENT For the nine months ended December 31, 2009 and 2008 2009 HK$000 (unaudited) 2008 HK$000 (unaudited) Revenue 254,244 296,388 Cost of sales (144,241 ) (174,359 ) Gross profit 110,003 122,029 Other income and gains, net 16,652 13,978 Selling and distribution costs] [MAN SANG INTERNATIONAL (B.V.I.) LIMITED By Cheng Chung Hing, Ricky]
JFC [JPMORGAN CHINA REGION FUND,] NSAR-B: jfchinaauditletter.htm 2 EX-99.77B ACCT LTTR
[jfchinaauditletter.htm 2 EX-99.77B ACCT LTTR]
CNR [CHINA METRO-RURAL] 6-K: MAN SANG INTERNATIONAL (B.V.I.) LIMITED UNAUDITED CONDENSED CONSOLIDATED
[MAN SANG INTERNATIONAL (B.V.I.) LIMITED UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENT For the nine months ended December 31, 2009 and 2008 2009 HK$000 (unaudited) 2008 HK$000 (unaudited) Revenue 254,244 296,388 Cost of sales (144,241 ) (174,359 ) Gross profit 110,003 122,029 Other income and gains, net 16,652 13,978 Selling and distribution costs] [MAN SANG INTERNATIONAL (B.V.I.) LIMITED By Cheng Chung Hing, Ricky]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]
